PDGF Inhibitors
1 drugsAbout PDGF
Platelet-derived growth factor (PDGF) is a protein involved in cell growth and division, crucial for various biological processes. It plays a significant role in cell proliferation and angiogenesis, making it a target for therapeutic intervention.
PDGF has garnered attention as a drug target, particularly in oncology, due to its involvement in tumor growth and spread. Currently, there is no genetic evidence directly linking PDGF to specific diseases.
There is one FDA-approved drug, Gefitinib, targeting the PDGF pathway for oncology indications. Gefitinib, marketed by Cipla, was first approved in 2022 and is a small molecule.
Top PDGF Drugs
Cipla is the only company with an approved drug targeting PDGF.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges.
PDGF Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDGF, using small molecule modality.
Explore alternative modalities like antibodies or fusion proteins to differentiate from existing therapies.
PDGF Clinical Trials 71 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PDGF. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 13 | 1 | 3 | 93% |
| Phase 2 | 34 | 23 | 6 | 4 | 79% |
| Phase 3 | 17 | 10 | 3 | 4 | 77% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PDGF Drug Approval Timeline (2022 - 2022)
The first and only drug targeting PDGF was approved in 2022.
Recent entry indicates a potentially emerging area, but also a lack of established clinical precedent.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 52 (21 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PDGF. A trial counts if an approved drug acting on PDGF is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.